Monte Rosa Therapeutics to Present Updated MRT-2359 Phase 1/2 Study Results

Monte Rosa Therapeutics (Nasdaq: GLUE) will present updated interim results from the Phase 1/2 study of the GSPT1-directed molecular glue degrader MRT-2359 in heavily pretreated metastatic castration-resistant prostate cancer (mCRPC) patients.

Rhea-AI Summary

Monte Rosa Therapeutics (Nasdaq: GLUE) will present updated interim results from the Phase 1/2 study of the GSPT1-directed molecular glue degrader MRT-2359 in heavily pretreated metastatic castration-resistant prostate cancer (mCRPC) patients.

The company will host a live conference call and webcast on December 16, 2025 at 8:00 a.m. ET. The presentation will be available via Monte Rosa’s investor site under “Events & Presentations,” and an archived webcast will be accessible for 30 days after the event.

Argus Dec 16 session

+13.43% close to close Open Argus

Details

News Market Reaction – GLUE

On Dec 16, the first trading day after this news, GLUE closed 13.43% above the previous close.

Data tracked by StockTitan Argus for the Dec 16 session.

Key Figures

Conference time: 8:00 a.m. ET Conference date: December 16, 2025 Study phase: Phase 1/2 +1 more

Conference time

8:00 a.m. ET

Scheduled webcast on December 16, 2025

Conference date

December 16, 2025

MRT-2359 Phase 1/2 interim results presentation

Study phase

Phase 1/2

Ongoing MRT-2359 study in mCRPC

Webcast archive duration

30 days

Archived webcast availability after presentation

Historical Context

5 past events · Latest: Nov 06

5 events

1. Nov 06

   Earnings & updates

   24h Move

   +5.7%

   Q3 2025 results plus Novartis collaboration and clinical pipeline progress.

2. Nov 03

   Investor conferences

   24h Move

   -6.1%

   Planned CEO participation in multiple healthcare investor conferences.

3. Oct 24

   Preclinical data

   24h Move

   +7.3%

   Preclinical MRT-6160 data showing broad immune activity and disease reduction.

4. Sep 15

   Strategic partnership

   24h Move

   +44.1%

   Major Novartis collaboration with large upfront and milestone potential.

5. Sep 02

   Investor conferences

   24h Move

   +2.5%

   Announcements of attendance at Morgan Stanley and Stifel healthcare events.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

molecular glue degrader, GSPT1-directed, metastatic castration-resistant prostate cancer, mCRPC

4 terms

molecular glue degrader medical

"a clinical-stage biotechnology company developing novel molecular glue degrader (MGD)-based medicines"

A molecular glue degrader is a small drug-like molecule that acts like a tiny adhesive, sticking a specific disease-related protein to the cell’s natural disposal machinery so the protein is destroyed rather than merely blocked. Investors watch these compounds because they can turn previously untreatable targets into removable liabilities, potentially creating breakthrough therapies, shifting development risk, and offering strong commercial upside if clinical results and regulatory approval follow.

GSPT1-directed medical

"Phase 1/2 study of the GSPT1-directed MGD MRT-2359"

GSPT1-directed describes a therapy designed to target the GSPT1 protein, a molecule involved in the final step of making other proteins inside cells. By disabling or destroying GSPT1, these treatments aim to stop growth or trigger death in certain cancer cells; think of it as cutting the power to a factory’s packaging line so defective products can’t leave. For investors, this indicates a specific mechanism that can drive efficacy, safety profiles, biomarker strategies, and regulatory interest.

metastatic castration-resistant prostate cancer medical

"in heavily pretreated, metastatic castration-resistant prostate cancer (mCRPC) patients"

An advanced form of prostate cancer that has spread beyond the prostate to other parts of the body (metastatic) and no longer responds to treatments that lower male hormones designed to starve the tumor (castration-resistant). It matters to investors because it defines a high unmet medical need with limited treatment options, so clinical trial results, new drug approvals, or safety setbacks can sharply change the valuation and prospects of companies working in this area; think of it as a weed that has spread and become resistant to the usual weedkiller.

mCRPC medical

"metastatic castration-resistant prostate cancer (mCRPC) patients"

mCRPC stands for metastatic castration‑resistant prostate cancer, a form of prostate cancer that has spread beyond the prostate and keeps progressing despite treatments that lower male hormones. It matters to investors because this stage is harder to treat, drives demand for new therapies, and often involves large, expensive clinical trials and regulatory decisions that can strongly influence a drug maker’s future revenue and stock value—think of it as a stubborn problem that creates both medical need and commercial opportunity.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Conference call and webcast to be held at 8 a.m. ET on December 16, 2025

BOSTON, Dec. 15, 2025 (GLOBE NEWSWIRE) -- Monte Rosa Therapeutics, Inc. (Nasdaq: GLUE), a clinical-stage biotechnology company developing novel molecular glue degrader (MGD)-based medicines, today announced that management will host a live conference call and webcast on Tuesday, December 16, 2025, at 8:00 a.m. ET. The webcast presentation will highlight interim clinical results from the ongoing Phase 1/2 study of the GSPT1-directed MGD MRT-2359 in heavily pretreated, metastatic castration-resistant prostate cancer (mCRPC) patients.

A webcast of the presentation will be accessible via the “Events & Presentations” section of Monte Rosa’s website at ir.monterosatx.com. Registration for the conference call is available at the following link. An archived version of the webcast will be made available for 30 days following the presentation.

About Monte Rosa
Monte Rosa Therapeutics is a clinical-stage biotechnology company developing highly selective molecular glue degrader (MGD) medicines for patients living with serious diseases. MGDs are small molecule protein degraders that have the potential to treat many diseases that other modalities, including other degraders, cannot. Monte Rosa’s QuEEN™ (Quantitative and Engineered Elimination of Neosubstrates) discovery engine combines AI-guided chemistry, diverse chemical libraries, structural biology, and proteomics to rationally design MGDs with unprecedented selectivity. Monte Rosa has developed the industry’s leading pipeline of first-in-class and only-in-class MGDs, spanning autoimmune and inflammatory diseases, oncology, and beyond, with three programs in the clinic. Monte Rosa has ongoing collaborations with leading pharmaceutical companies in the areas of immunology, oncology and neurology. For more information, visit www.monterosatx.com.

Investors
Andrew Funderburk
ir@monterosatx.com

Media
Cory Tromblee, Scient PR
media@monterosatx.com

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

When will Monte Rosa Therapeutics (GLUE) present MRT-2359 Phase 1/2 interim results?

Management will present on December 16, 2025 at 8:00 a.m. ET.

What patient population is included in the MRT-2359 Phase 1/2 update for GLUE?

The update covers interim results in heavily pretreated metastatic castration-resistant prostate cancer (mCRPC) patients.

How can investors watch the Monte Rosa (GLUE) MRT-2359 presentation?

Watch live via the webcast on Monte Rosa’s investor site under Events & Presentations or join the conference call after registering.

Will the MRT-2359 webcast for GLUE be available after the live presentation?

Yes, an archived version will be available for 30 days following the presentation.

What drug is being discussed in Monte Rosa’s (GLUE) December 16, 2025 presentation?

The presentation highlights interim clinical results for the GSPT1-directed molecular glue degrader MRT-2359.

Is registration required to join Monte Rosa Therapeutics (GLUE) conference call for MRT-2359 results?

Yes, registration is available via the company’s provided conference call link.